Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
PFIZER INC (PFE.DE) Stock Price & Overview
FRA:PFE • US7170811035
Current stock price
22.8 EUR
+0.26 (+1.15%)
Last:
The current stock price of PFE.DE is 22.8 EUR. Today PFE.DE is up by 1.15%. In the past month the price decreased by -5.84%. In the past year, price increased by 7.32%.
PFE.DE Key Statistics
52-Week Range19.318 - 24.92
Current PFE.DE stock price positioned within its 52-week range.
1-Month Range22.43 - 24.92
Current PFE.DE stock price positioned within its 1-month range.
- Market Cap
- 129.695B
- P/E
- 8.26
- Fwd P/E
- 8.93
- EPS (TTM)
- 2.76
- Dividend Yield
- 6.44%
PFE.DE Stock Performance
Today
+1.15%
1 Week
+0.82%
1 Month
-5.84%
3 Months
+3.47%
Longer-term
6 Months +6.99%
1 Year +7.32%
2 Years -5.28%
3 Years -35.14%
5 Years -28.79%
10 Years N/A
PFE.DE Stock Chart
PFE.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE turns out to be only a medium performer in the overall market: it outperformed 49.11% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PFE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. While PFE.DE is still in line with the averages on profitability rating, there are concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PFE.DE Earnings
On February 3, 2026 PFE.DE reported an EPS of 0.66 and a revenue of 17.56B. The company beat EPS expectations (14.29% surprise) and beat revenue expectations (2.56% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 3, 2026
PeriodQ4 / 2025
EPS Reported$0.66
Revenue Reported17.557B
EPS Surprise 14.29%
Revenue Surprise 2.56%
PFE.DE Forecast & Estimates
35 analysts have analysed PFE.DE and the average price target is 25.11 EUR. This implies a price increase of 10.14% is expected in the next year compared to the current price of 22.8.
For the next year, analysts expect an EPS growth of -7.47% and a revenue growth -1.14% for PFE.DE
Analysts
Analysts69.71
Price Target25.11 (10.13%)
EPS Next Y-7.47%
Revenue Next Year-1.14%
PFE.DE Financial Highlights
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.76. The EPS increased by 3.86% compared to the year before.
Income Statements
Revenue(TTM)62.58B
Net Income(TTM)7.77B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.42% | ||
| ROA | 3.73% | ||
| ROE | 8.99% | ||
| Debt/Equity | 0.71 |
Chartmill High Growth Momentum
EPS Q2Q%4.76%
Sales Q2Q%-1.16%
EPS 1Y (TTM)3.86%
Revenue 1Y (TTM)-1.64%
PFE.DE Ownership
Ownership
Inst Owners67.72%
Shares5.69B
Float5.68B
Ins Owners0.02%
Short Float %N/A
Short RatioN/A
PFE.DE Industry Overview
PFE.DE operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
42%
Outperformed 42% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 96.3%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 41.4%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.8
- Average Debt/Equity
- 1.3
PFE.DE Competitors/Peers
The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 8.79 | 96.756B | ||
| SNW | SANOFI | 8.79 | 96.756B | ||
| 1SAN | SANOFI | 8.6 | 94.671B | ||
| 1MRK | MERCK KGAA | 13.79 | 51.435B | ||
| MRK | MERCK KGAA | 13.95 | 47.848B | ||
| UCB | UCB SA | 21.9 | 44.971B | ||
| UNC | UCB SA | 21.24 | 43.629B | ||
| 1BAYN | BAYER AG-REG | 8.66 | 37.43B | ||
| BAYN | BAYER AG-REG | 8.65 | 37.381B | ||
| IPN | IPSEN | 13.19 | 13.996B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.7 | 10.381B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 8.711B | ||
| VIRP | VIRBAC SA | 17.37 | 3.117B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PFE.DE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
IPO: 1944-01-17
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 75000
Phone: 13026587581
PFIZER INC / PFE.DE FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Can you provide the latest stock price for PFIZER INC?
The current stock price of PFE.DE is 22.8 EUR. The price increased by 1.15% in the last trading session.
What is the dividend status of PFIZER INC?
PFIZER INC (PFE.DE) has a dividend yield of 6.44%. The yearly dividend amount is currently 1.47.
What is the ChartMill rating of PFIZER INC stock?
PFE.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is PFIZER INC (PFE.DE) expected to grow?
The Revenue of PFIZER INC (PFE.DE) is expected to decline by -1.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for PFIZER INC?
PFIZER INC (PFE.DE) has a market capitalization of 129.69B EUR. This makes PFE.DE a Large Cap stock.
What is the ownership structure of PFIZER INC (PFE.DE)?
You can find the ownership structure of PFIZER INC (PFE.DE) on the Ownership tab.